PetMed Express director granted 33,846 restricted shares (Form 4)

Q: What did PETS disclose in this Form 4?

A director received a restricted stock award of 33,846 common shares on 10/30/2025.

Q: What is the vesting schedule for the PETS director award?

The restricted shares vest in full on October 30, 2026, subject to continued Board service.

Q: How many PETS shares does the reporting person own after the transaction?

The director beneficially owned 36,373 shares following the grant, held directly.

Q: What price was paid for the PETS restricted stock award?

The reported price was $0, consistent with a restricted stock grant.

Q: Under which plan was the PETS award granted?

The award was made under the PetMed Express, Inc. 2024 Omnibus Incentive Plan.

Q: What type of security was granted to the PETS director?

The filing reports common stock granted as a restricted stock award.

PetMed Express (PETS) reported a director equity grant on a Form 4.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

PetMed Express (PETS) reported a director equity grant on a Form 4. On 10/30/2025, the director acquired 33,846 shares of common stock as a restricted stock award at a reported price of $0, under the company’s 2024 Omnibus Incentive Plan. Following the grant, the director beneficially owned 36,373 shares, held directly.

The award vests in full on October 30, 2026, subject to continued service on the Board of Directors.

Insider Trade Summary

Grant/Award: 33,846 shares

Grant/Award 1 txn

Insider Batushansky Peter

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	33,846	$0.00	$0.00

Holdings After Transaction: Common Stock — 36,373 shares (Direct)

Footnotes (1)

F1. Consists of a restricted stock award made pursuant to the PetMed Express, Inc. 2024 Omnibus Incentive Plan that vests as to all granted shares on October 30, 2026, subject to continued service on the Board of Directors.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PETS disclose in this Form 4?

A director received a restricted stock award of 33,846 common shares on 10/30/2025.

What is the vesting schedule for the PETS director award?

The restricted shares vest in full on October 30, 2026, subject to continued Board service.

How many PETS shares does the reporting person own after the transaction?

The director beneficially owned 36,373 shares following the grant, held directly.

What price was paid for the PETS restricted stock award?

The reported price was $0, consistent with a restricted stock grant.

Under which plan was the PETS award granted?

The award was made under the PetMed Express, Inc. 2024 Omnibus Incentive Plan.

What type of security was granted to the PETS director?

The filing reports common stock granted as a restricted stock award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 11/03/2025 - 04:05 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Batushansky Peter

(Last)

(First)

(Middle)

C/O PETMED EXPRESS, INC.

420 SOUTH CONGRESS AVENUE

(Street)

DELRAY BEACH

33445

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
PETMED EXPRESS INC [ PETS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/30/2025		A		33,846⁽¹⁾	A	$0	36,373	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Consists of a restricted stock award made pursuant to the PetMed Express, Inc. 2024 Omnibus Incentive Plan that vests as to all granted shares on October 30, 2026, subject to continued service on the Board of Directors.

Remarks:

	/s/ Peter Batushansky	11/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR